BiotechTube

PF-02545920 + Placebo + PF-02545920 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Sep 1, 2013 → Jan 1, 2015

NCT ID
NCT01806896

About PF-02545920 + Placebo + PF-02545920 + Placebo

PF-02545920 + Placebo + PF-02545920 + Placebo is a phase 2 stage product being developed by Pfizer for Huntington's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01806896. Target conditions include Huntington's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01806896Phase 2Completed

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
52
RO7234292 (RG6042)RochePhase 2
52
RG6496 + PlaceboRochePhase 1
33
PF-02545920 + PF-02545920PfizerPhase 2
51
20 mg BID of PF-02545920PfizerPhase 2
51
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
30
TetrabenazineLundbeckApproved
82
BN82451B + PlaceboIpsenPhase 2
49
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
38
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
36
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
36
SAGE-718Supernus PharmaceuticalsPhase 3
72
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
47
OMS643762 + PlaceboOmeros CorporationPhase 2
47
VX15/2503 + PlaceboVaccinexPhase 2
44

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84